Brief: Tarsus Announces Positive Topline Data From Saturn-2 Phase 3, Second Pivotal Trial Of Tp-03 For Treatment Of Demodex Blepharitis

Tarsus Pharmaceuticals

02/05/2022 13:15

May 2 (Reuters) - Tarsus Pharmaceuticals Inc  TARS.O :
    * TARSUS ANNOUNCES POSITIVE TOPLINE DATA FROM SATURN-2 PHASE
3,
SECOND PIVOTAL TRIAL OF TP-03 FOR TREATMENT OF DEMODEX
BLEPHARITIS, AND EXPECTS TO FILE A NEW DRUG APPLICATION THIS
YEAR
    * TARSUS PHARMACEUTICALS INC - 56% OF PATIENTS ON TP-03
ACHIEVED
PRIMARY ENDPOINT OF COMPLETE COLLARETTE CURE
    * TARSUS PHARMACEUTICALS INC - TARSUS PLANS TO SUBMIT A NEW
DRUG
APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN
SECOND HALF OF 2022
    * TARSUS PHARMACEUTICALS INC - CONSISTENT WITH SATURN-1,
SATURN-2
TRIAL RESULTS DEMONSTRATED THAT TP-03 WAS WELL-TOLERATED WITH A
SAFETY PROFILE
    * TARSUS PHARMACEUTICALS- TP-03 (LOTILANER OPHTHALMIC
SOLUTION,
0.25%) MET PRIMARY ENDPOINT & ALL SECONDARY ENDPOINTS IN
SATURN-2 PIVOTAL PHASE 3 TRIAL

Source text for Eikon:  ID:nGNX76VmNq 
Further company coverage:  TARS.O 

 ((reuters.briefs@thomsonreuters.com;))